HMOX1 and infarction: Our findings support the putative role of pharmacological induction of HO-1 in the clinical setting, where medical therapy is always initiated after the onset of infarction, in order to obtain benefits in both infarcted and remote territories, leading to better cardiac function and auspiciously to better medium- to long-term outcome.